A
2.72
0.02 (0.74%)
Previous Close | 2.70 |
Open | 2.75 |
Volume | 141,205 |
Avg. Volume (3M) | 439,045 |
Market Cap | 53,002,464 |
Price / Book | 2.46 |
52 Weeks Range | |
Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
Diluted EPS (TTM) | -2.24 |
Current Ratio (MRQ) | 10.68 |
Operating Cash Flow (TTM) | -22.96 M |
Levered Free Cash Flow (TTM) | -13.95 M |
Return on Assets (TTM) | -91.05% |
Return on Equity (TTM) | -280.78% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Annovis Bio, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.9
Analyst Consensus | -0.5 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -2.5 |
Average | -1.88 |
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 14.69% |
% Held by Institutions | 16.09% |
Ownership
Name | Date | Shares Held |
---|---|---|
Lokken Investment Group Llc | 31 Mar 2025 | 29,235 |
52 Weeks Range | ||
Median | 12.00 (341.18%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 09 Jun 2025 | 12.00 (341.18%) | Buy | 3.06 |
No data within this time range.
Date | Type | Details |
---|---|---|
12 Aug 2025 | Announcement | Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results |
07 Aug 2025 | Announcement | Annovis Completes Full Patent Transfer to Crystal Buntanetap |
26 Jun 2025 | Announcement | Annovis to Attend the AAIC 2025 with Four Poster Presentations |
19 Jun 2025 | Announcement | Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance |
05 Jun 2025 | Announcement | Annovis to Host Webinar and Live Q&A on June 24, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |